Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA
Reliable biomarkers are required to evaluate and manage pancreatic ductal adenocarcinoma. Circulating tumor cells and circulating tumor DNA are shed into blood and can be relatively easily obtained from minimally invasive liquid biopsies for serial assays and characterization, thereby providing a un...
Main Authors: | Jee‐Soo Lee, Sung Sup Park, Young Kyung Lee, Jeffrey A. Norton, Stefanie S. Jeffrey |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-08-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12537 |
Similar Items
-
Application of liquid biopsy for surgical management of pancreatic cancer
by: Minako Nagai, et al.
Published: (2020-05-01) -
Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcinoma
by: Kajsa E. Affolter, et al.
Published: (2021-09-01) -
Current Status of Circulating Tumor DNA Liquid Biopsy in Pancreatic Cancer
by: Miles W. Grunvald, et al.
Published: (2020-10-01) -
Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives
by: Verena Martini, et al.
Published: (2019-10-01) -
Liquid Biopsy in 2017: Circulating Tumor Cells and Circulating Tumor DNA in Precision Medicine
by: Lei CAI, et al.
Published: (2017-03-01)